CBSET Appoints Director of Business Development

CBSET Inc. has appointed Michael Naimark as director of business development, effective immediately. Most recently, he was employed by the Neural Stem Cell Institute (NSCI) as project manager overseeing the development of a cell-based therapy for macular degeneration under a four-year award from the New York Stem Cell Foundation.
 
Previously, Naimark was co-owner of Care Research, a preclinical research organization where he provided operational, sales, and marketing oversight as director of surgical models. Prior to founding Care Research, he helped launch Preclinical Research Services Inc., a preclinical research organization, and served as senior study director for several years.
 
“We are very pleased to have Michael join CBSET,” said Peter M. Markham, president and CEO. “His significant hands-on experience in managing complex preclinical studies in a variety of animal models puts him in a unique position to interact on CBSET’s behalf with existing and potential new sponsors about study goals and regulatory requirements. His industry experience and knowledge of cell-based and biologics therapies are a valuable addition to the CBSET team.”
 
Naimark earned a master of science degree in neurobiology and anatomy at the University of Tennessee Health Sciences Center, and a bachelor of science degree in biology/biological sciences at the University of Mississippi. He holds certificates in medical device regulatory affairs and biologics regulatory affairs from Colorado State University and is the co-author of seven published scientific papers.

“CBSET has an outstanding reputation in the industry as a CRO that combines high-level technical expertise and rigorous regulatory compliance on behalf of its clients,” said Naimark. “I’m very excited about joining CBSET and look forward to working with the team to expand service offerings into new therapeutic areas while maintaining the dedication to quality that has been the foundation of the company.”
 
CBSET Inc., based in Lexington, Mass., is the preclinical research leader in critically important therapeutic fields such as interventional cardiology, renal disease and dialysis, chronic drug-resistant hypertension, women’s health, minimally invasive surgery, orthopedics, biological and synthetic tissue repair, drug delivery, bioresorbable devices, and combination medical device and drug-eluting products.